Molecular pharmacokinetic determinants of anticancer kinase inhibitors in humans

Scholler, Julie; Levêque, Dominique

doi:10.4081/oncol.2011.77

Cited by 11 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…EGFR-TKIs cause a rapid decrease in target receptors by killing the EGFR mutation-harboring target cells, but objective evaluation of this phenomenon is thought to be difficult because systematic radiological evaluation of tumor size was not done in the early phase of treatment. Gefitinib has a longer t 1/2 and a larger tissue distribution than erlotinib [9,10]. Thus, the pharmacological parameters might be easily affected by the decreased number of target receptors.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations

Mizoguchi

Nakamura

Sano

et al. 2016

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations

Mizoguchi

Nakamura

Sano

et al. 2016

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

show abstract

“…The initial oral cancer therapy agents, methotrexate and mercaptopurine, were approved in 1953 and have been obtainable in the United States for over half a century . To date, the number of oral cancer therapy drugs approved by the Food and Drug Administration has continued to increase, with more than 60 currently approved for use . Given the increasing incidence of cancer, it is expected that more patients will receive oral cancer treatment in the coming decades .…”

Section: Discussionmentioning

confidence: 99%

Geraniin inhibits oral cancer cell migration by suppressing matrix metalloproteinase‐2 activation through the FAK/Src and ERK pathways

Yeh

Hsieh

Yang

et al. 2019

Environmental Toxicology

View full text Add to dashboard Cite

Geraniin has been reported to have numerous biological activities, including antiviral, antihypertensive, antihyperglycaemic, liver protective, antidiabetic, and apoptotic activities. However, the anti‐migration effects of geraniin on oral cancer remain elusive. In this study, we revealed the potential antitumor mechanisms of geraniin through the inhibition of the migration and invasion of human oral cancer cell lines SCC‐9 and SCC‐14. The results of gelatin zymography and Western blot assays revealed that geraniin significantly reduced the activity and expression of matrix metalloproteinase‐2 (MMP‐2) of oral cancer cells in a concentration‐dependent manner. Furthermore, geraniin potently suppressed the phosphorylation of focal adhesion kinase (FAK), Src, and extracellular signal‐regulated kinase (ERK)1/2 but did not affect the phosphorylation of p38 mitogen‐activated protein kinase (MAPK) and c‐Jun N‐terminal kinase 1/2. Moreover, blocking the MAPK/ERK1/2 pathway significantly enhanced the anti‐migration ability of geraniin in oral cancer cells. In conclusion, we demonstrated that geraniin inhibits the motility of SCC‐9 and SCC‐14 cells in vitro through a molecular mechanism that involves the attenuation of MMP‐2 expression and activity mediated by decreased FAK/Src and ERK1/2 pathways.

show abstract

“…The number of orally available chemotherapy agents has significantly increased in the past decade, with more than 60 agents currently approved in the USA. 22 Additionally, 20%–30% of chemotherapy agents in the development pipeline will be administered orally. 23 Recent studies of the oral chemotherapy medication use process identified key vulnerabilities, including patient education about drug handling and adverse effects, prescription writing, monitoring, and toxicity management, and highlighted the need to adopt rigorous safety standards.…”

Section: Resultsmentioning

confidence: 99%

Chemotherapy e-prescribing: opportunities and challenges

Elsaid

Garguilo

Collins

2015

IPRP

View full text Add to dashboard Cite

Chemotherapy drugs are characterized by low therapeutic indices and significant toxicities at clinically prescribed doses, raising serious issues of drug safety. The safety of the chemotherapy medication use process is further challenged by regimen complexity and need to tailor treatment to patient status. Errors that occur during chemotherapy prescribing are associated with serious and life-threatening outcomes. Computerized provider order entry (CPOE) systems were shown to reduce overall medication errors in ambulatory and inpatient settings. The adoption of chemotherapy CPOE is lagging due to financial cost and cultural and technological challenges. Institutions that adopted infusional or oral chemotherapy electronic prescribing modified existing CPOE systems to allow chemotherapy prescribing, implemented chemotherapy-specific CPOE systems, or developed home-grown chemotherapy electronic prescribing programs. Implementation of chemotherapy electronic prescribing was associated with a significant reduction in the risk of prescribing errors, most significantly dose calculation and adjustment errors. In certain cases, implementation of chemotherapy CPOE was shown to improve the chemotherapy use process. The implementation of chemotherapy CPOE may increase the risk of new types of errors, especially if processes are not redesigned and adapted to CPOE. Organizations aiming to implement chemotherapy CPOE should pursue a multidisciplinary approach engaging all stakeholders to guide system selection and implementation. Following implementation, organizations should develop and use a risk assessment process to identify and evaluate unanticipated consequences and CPOE-generated errors. The results of these analyses should serve to further enhance the chemotherapy electronic prescribing process and improve the quality and safety of cancer care.

show abstract

Molecular pharmacokinetic determinants of anticancer kinase inhibitors in humans

Cited by 11 publications

References 0 publications

Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations

Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations

Geraniin inhibits oral cancer cell migration by suppressing matrix metalloproteinase‐2 activation through the FAK/Src and ERK pathways

Chemotherapy e-prescribing: opportunities and challenges

Contact Info

Product

Resources

About